Announcements
Sidley Represents Restive Ventures in Formation of US$45 Million Restive Fund III
May 29, 2026
Sidley represented Restive Ventures in the formation of its third fund, Restive Fund III, which closed with US$45 million in commitments. Focused on investments in AI-related fintech companies, the fund attracted a new range of strategic investors, including banks and financial institutions, payments firms, and technology companies focused on AI innovation across the financial services sector.
Based in San Francisco, Restive Ventures invests in pre-seed and seed-stage companies at the intersection of financial services and emerging technologies. More information about the transaction is available here.
The Sidley team was led by Rob Carlson and included John Schaff, Yusuke Kubo, Andrea Villarreal, and Zhize Wang.
Contacts
Capabilities
Suggested News & Insights
Sidley Represents Aquestive Therapeutics in Exclusive U.S. Licensing Agreement With Eton PharmaceuticalsOctober 16, 2026Sidley Represents Nous Research in US$90 Million Series B FinancingOctober 12, 2026Sidley Represents GE HealthCare in Its US$945 Million Acquisition of SOFIE BiosciencesOctober 7, 2026Sidley Represents Jiangsu Nhwa Pharmaceutical in Its US$517.5 Million Licensing Transaction With SomniveraSeptember 30, 2026Sidley Represents Bluevine in Its US$340 Million Acquisition by Valley National BankSeptember 28, 2026Sidley Represents Star51 Capital in Its Investment in UltraSight’s US$24 Million FinancingSeptember 25, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory




